Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [1]
(Cell-free assay)
90 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fGOFXDqM7:TR?= Mor6OFjDqGh? MYXicI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> MWCyOlM2ODV4NR?=
NP69 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zYUGlEPTB;M{GuOlnDuTJwNUSg{txO MkXZNlYzPTJ3N{W=
NP460 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fud2lEPTB;MkKuPFXDuTFwMUig{txO M1nLdlI3OjV{NUe1
C666-1 NVfL[Wh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6yfYtSUUN3ME2xPU46PcLzOD65N{DPxE1? M{PtflI3OjV{NUe1
C666-1 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWSxNEDDvU1? NHHTfnU1QCCq NYT2T2NDTE2VTx?= MV\z[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iClaYPwcIF1cW5? MYGyOlI2OjV5NR?=
C666-1  MlizSpVv[3Srb36gRZN{[Xl? Mnu0NVAhyrWP MoD2NlQhcA>? MXrEUXNQ MU\hZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> NInQcpczPjJ3MkW3OS=>
C666-1 NHjPVoZCeG:ydH;zbZMhSXO|YYm= NHKzfIsyOCEEtV2= NGHHe4g1QC95MjDo NHK0TmNFVVOR NFi0ToN{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NVrST3RrOjZ{NUK1O|U>
A549 M13kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtNnYzPCCq MXXJR|UxRTF5Lk[4JOKyKDRwNUKg{txO MWmyOlEzPTJ|MB?=
A549-NTC M{HHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnSZYZZOjRiaB?= NWW2W25jUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= MYqyOlEzPTJ|MB?=
A549-920 NH3BZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3PFI1KGh? MnnMTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? M1S4blI3OTJ3MkOw
CRL-5908 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPbZYzPCCq M3H4cGlEPTB;M{iuO|EhyrFiMj60N{DPxE1? NUK5SGNQOjZzMkWyN|A>
L6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DaU|ExyqEQvF5CpC=> NVjvNFVMOjRxNEivO|IhcA>? MlvGSG1UVw>? M2fQSYlvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? NEG2Z5gzPTh5MUe5OC=>
C2C12 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrkd|AyOMLizszNxsA> MnvONlQwPDhxN{KgbC=> NGjsbZRFVVOR Mnv1bY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v MnLZNlU5PzF5OUS=
MCF-7  NV7tSXhyTnWwY4Tpc44hSXO|YYm= NX;BNG5tOTEEoN88US=> MoP5SG1UVw>? M37vdYlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? MlTqNlU4ODJ5MEO=
DU4475  MnPvSpVv[3Srb36gRZN{[Xl? MnvIOU8yOC9{MDFOwG0> NHezfo8zPMLiaB?= NH7YeG9ld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 M{jY[FI2PTR5MUe0
SMMC-7721 MWLGeY5kfGmxbjDBd5NigQ>? MlP6NVAh|ryP MVW0PEBp NVvFdVlkTE2VTx?= MnTUZ4F2e2W|IFTORUBFW0JiZHHtZYdm M4TSeVI2PTR2M{[x
SMMC-7721 NFv3dFNHfW6ldHnvckBCe3OjeR?= NFHISGEyOCEQvF2= NI\XPYo1QCCq MYLEUXNQ MmDabY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> NITxUXMzPTV2NEO2NS=>
SMMC-7721 MkKySpVv[3Srb36gRZN{[Xl? MVexNEDPxE1? M1fFdFQ5KGh? NFyxPIJFVVOR M4HIUIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> MWmyOVU1PDN4MR?=
SMMC-7721 MXHGeY5kfGmxbjDBd5NigQ>? MX6xNEDPxE1? NHzVbIQ{PiCq M3TsfWROW09? MkDjZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NX7Rc5RtOjV3NESzOlE>
MCF-7 M{HJSGZ2dmO2aX;uJGF{e2G7 M3jkbFExyqEQvF2= MmewNE0zPCCq NXO2[VVXcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx NGDmRYwzPTR6MkO3Ny=>
OVCAR10 NYT4RXpoTnWwY4Tpc44hSXO|YYm= NUe2cm9ZOTEEoN88US=> NEG2eJgzOWkEoB?= MVnEUXNQ MYLpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M3TrelI2PDJ4NUS4
NCI-H23 MkLYSpVv[3Srb36gRZN{[Xl? MVuxNOKh|ryP NEWxVHQzOWkEoB?= M2Oz[mROW09? MlOzbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MV:yOVQzPjV2OB?=
A2780 M3nhZmZ2dmO2aX;uJGF{e2G7 NVvDUGFUOTEEoN88US=> M{Hm[FIycMLi MX7EUXNQ M2S0c4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NIS2fIIzPTR{NkW0PC=>
NCI-H23 NIfPTm9HfW6ldHnvckBCe3OjeR?= NF;4[mYyOMLizszN M4OwclIycMLi MkXWSG1UVw>? NIryWmRl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NUTDVFdHOjV2Mk[1OFg>
A2780 NH:3dYtHfW6ldHnvckBCe3OjeR?= NYjRemNNOTEEoN88US=> MWiyNYjDqA>? MkfLSG1UVw>? M1vuSYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz M{LtXlI2PDJ4NUS4
HCT116  NUL5bJAxTnWwY4Tpc44hSXO|YYm= NVf2O5Y1OTBiwsXN M1TUVlI1KGh? NVTZfopZ[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NYG2N4JpOjV|OECwOVU>
MCF-10CA1a M1HBSWZ2dmO2aX;uJGF{e2G7 NY\NdVZ3OTEEoN88US=> NIPOeYg1QCCq NFfvdFJFVVOR NX;z[oRJcW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= M{f5[VI2OjV5N{K5
MCF-10A1  NV\yUodiTnWwY4Tpc44hSXO|YYm= MXixNOKh|ryP MViyOE81QCCq NHviUFJFVVOR MVrpcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG|dDDldIl1cGWuaXHsxsA> NETpOmIzPTJ3N{eyPS=>
MCF-10CA1a NGSweGpHfW6ldHnvckBCe3OjeR?= MVKxNOKh|ryP NXXOO2I6OjRiaB?= NH7FO3hFVVOR MUPk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? NGLmTYIzPTJ3N{eyPS=>
MCF-10CA1a MWTGeY5kfGmxbjDBd5NigQ>? MXqxNOKh|ryP Mmm0NlQhcA>? MoL5SG1UVw>? M3\sTIlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NYnhN3FnOjV{NUe3Nlk>
SK-BR-7 NX\wWHA1TnWwY4Tpc44hSXO|YYm= MYexNOKh|ryP M4nuRlI1KGh? MknmSG1UVw>? MXXpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MWSyOVI2Pzd{OR?=
SUM102PT M3fuemZ2dmO2aX;uJGF{e2G7 MojiNVDDqM7:TR?= M1j4cFI1KGh? MkfzSG1UVw>? M2\HfolvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MnniNlUzPTd5Mkm=
RAW 264.7 NUHCVFdQTnWwY4Tpc44hSXO|YYm= M4\WclExyqEQvF2= MkWzN|AhdWmw NUnmVolveHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU MmrhNlUyPzJ3NEe=
RAW 264.7 Mn\zSpVv[3Srb36gRZN{[Xl? NIi5[2QyOMLizszN NV3ZWHA{OzBibXnu NVHiV4I3emWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> NYXSTXpvOjVzN{K1OFc>
RAW 264.7 MX\GeY5kfGmxbjDBd5NigQ>? M{\QeVExyqEQvF2= Mn2wN|AhdWmw NV3ySVZEcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh NIPZOlIzPTF5MkW0Oy=>
MCF7  NEewT3lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4T1SFIvPSEEtV2= NY\wNHBtPSCm MXHEUXNQ M1HWOpNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= M2m0PVI2ODh3OUCy
MCF7  M4C1XGZ2dmO2aX;uJGF{e2G7 NX7PZVFtOi53INM1US=> M1uwR|Q5KGh? MXnEUXNQ NIftSWNl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? M4j2RlI2ODh3OUCy
ACHN M2rzVGNmdGxiVnnhZoltcXS7IFHzd4F6 NVP4NnJnOC53LUGwJO69VQ>? MmjUNE03KGR? MnS1SG1UVw>? NIjrbnVqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoPvNlUxPjd5OEe=
Caki-2 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml7pNE42NTFyIN88US=> NHTzRpIxNTZiZB?= M3;4eWROW09? MorybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXiyOVA3Pzd6Nx?=
A498 MlrNR4VtdCCYaXHibYxqfHliQYPzZZk> NYG4b2x1OC53LUGwJO69VQ>? MnzKNE03KGR? NH6yVHhFVVOR NIL0W4lqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2DnflI2ODZ5N{i3
115 M{KyS2NmdGxiVnnhZoltcXS7IFHzd4F6 NFK0eXkxNjVvMUCg{txO M4\IXlAuPiCm MWHEUXNQ M1\MfYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX2yOVA3Pzd6Nx?=
117 M1HzOGNmdGxiVnnhZoltcXS7IFHzd4F6 NVrtXnluOC53LUGwJO69VQ>? M37jZ|AuPiCm M{nJUWROW09? NWexd4tJcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIWx[JkzPTB4N{e4Oy=>
ACHN MVHGeY5kfGmxbjDBd5NigQ>? NYDVenZ[OC53L{GvOUDPxE1? MX:0PEBp NG\URWVFVVOR Mlj1cIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NY\oZnFpOjVyNke3PFc>
Caki-2 M2LRW2Z2dmO2aX;uJGF{e2G7 MUmwMlUwOS93IN88US=> NH7wUHk1QCCq M1rZfGROW09? NWrhSZZNdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NHfZ[XkzPTB4N{e4Oy=>
A498 M{nGSWZ2dmO2aX;uJGF{e2G7 MVywMlUwOS93IN88US=> M4LFc|Q5KGh? NYXhPFNKTE2VTx?= M4DXdoxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NVTUZ4xDOjVyNke3PFc>
115 NX\WW49{TnWwY4Tpc44hSXO|YYm= NGTXOmwxNjVxMT:1JO69VQ>? MWO0PEBp MWPEUXNQ NUH1W3M{dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= M{LMNVI2ODZ5N{i3
ACHN M4LWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRclRiPSEQvF2= Ml\zOFghcA>? NETNclZFVVOR MlLLbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NXjFcHBJOjVyNke3PFc>
Caki-2 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPGRpZlPSEQvF2= MUm0PEBp NHnZdZdFVVOR M4PlVolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NULsdZk{OjVyNke3PFc>
A498 NUm0NI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPLPVM2KM7:TR?= NUG3TYFlPDhiaB?= NXjJ[HU{TE2VTx?= NW\JWXVScW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MVGyOVA3Pzd6Nx?=
115 NX[0UG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\IZ5R4PSEQvF2= Ml3QOFghcA>? M{nJRWROW09? NGSx[5lqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NF7E[YUzPTB4N{e4Oy=>
ACHN NHKze3ZHfW6ldHnvckBCe3OjeR?= NYjWO4U3PSEQvF2= MWG0PEBp M3PaeWROW09? Mn7kbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= M{L1dFI2ODZ5N{i3
Caki-2 MVTGeY5kfGmxbjDBd5NigQ>? MXW1JO69VQ>? MVS0PEBp NVi4U4U4TE2VTx?= NEnGOZJqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M4r1VVI2ODZ5N{i3
A498 MX7GeY5kfGmxbjDBd5NigQ>? M4TXW|Uh|ryP NXmxVFFRPDhiaB?= NV23bJlJTE2VTx?= M3;TRolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M1LOeFI2ODZ5N{i3
115 MnjISpVv[3Srb36gRZN{[Xl? MVW1JO69VQ>? NUmxWGFZPDhiaB?= MUnEUXNQ NF7oU5dqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MkPWNlUxPjd5OEe=
MOLM-13 MXXGeY5kfGmxbjDBd5NigQ>? MV62xsDPxE1? MlniNE05KGh? MmT2SG1UVw>? MlW2bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MonSNlQ5QDVyOEK=
MOLM-13 NVzqSVh{TnWwY4Tpc44hSXO|YYm= NHvSdGo3yqEQvF2= MnjEOkBp NE\ndmpFVVOR MmnP[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?= NVG5SpB6OjR6OEWwPFI>
HepG2 NYLxNW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LRWFczKGh? M1XPN2ROW09? Mnn0TWM2OD1|NT64OkDDuSB{Lkmg{txO MmfiNlQ5QDR6MEm=
HepG2/As MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHD[ZdKPzJiaB?= M3uwe2ROW09? NXXFcJpyUUN3ME22PE4yOyEEsTC5MlYh|ryP MVyyOFg5PDhyOR?=
SMMC7721 M3e1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zkNlczKGh? NWrKZmo1TE2VTx?= NHn6cmtKSzVyPUOxMlI5KMLzIESuNkDPxE1? Mkj6NlQ5QDR6MEm=
SMMC7721/Ac MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvrSXJUPzJiaB?= NWHBO3hVTE2VTx?= NI[0Oo9KSzVyPUW1MlIyKMLzIEWuNFMh|ryP MnOzNlQ5QDR6MEm=
Huh-7 NUPDW2NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37iPVczKGh? MVnEUXNQ M{nKe2lEPTB;M{OuPVYhyrFiMz65JO69VQ>? M4\aT|I1QDh2OEC5
Hep3B MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zGd|czKGh? NIP4RY9FVVOR NFi5S5ZKSzVyPUKwMlE5KMLzIEGuPFQh|ryP NUHTO|RqOjR6OES4NFk>
HepG2 M2XzSmFxd3C2b4Ppd{BCe3OjeR?= NFW0c4RqdmS3Y3XzJIFxd3C2b4Ppdy=> MXmyOFg5PDhyOR?=
SMMC7721 NF7kUY5CeG:ydH;zbZMhSXO|YYm= MULpcoR2[2W|IHHwc5B1d3Orcx?= MYWyOFg5PDhyOR?=
Huh-7 M{OwV2Fxd3C2b4Ppd{BCe3OjeR?= M1\V[Ilv\HWlZYOgZZBweHSxc3nz NInNcIQzPDh6NEiwPS=>
Hep3B NHPQeG9CeG:ydH;zbZMhSXO|YYm= MoLMbY5lfWOnczDhdI9xfG:|aYO= NXvlbGZnOjR6OES4NFk>
U2OS  Mn[1SpVv[3Srb36gRZN{[Xl? NEnucVMzOCEQvF2= MlG2NlQhcA>? MWLpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ MVWyOFg3PzJ3OR?=
AML2 MWjBdI9xfG:|aYOgRZN{[Xl? MnTVNk8yOCEQvF2= M4\pNFI1NzR6IHi= NYHrWHNwcW6mdXPld{BieG:ydH;zbZM> MkTCNlQ3PTl5NEm=
MOML13 NELBRphCeG:ydH;zbZMhSXO|YYm= MUWyM|ExKM7:TR?= M2LxVFI1NzR6IHi= NIf3dW9qdmS3Y3XzJIFxd3C2b4Ppdy=> Mo\FNlQ3PTl5NEm=
AML2 Mm[4SpVv[3Srb36gRZN{[Xl? MmPUNVDPxE1? MXuyM|QhcA>? M2rXWYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MnLZNlQ3PTl5NEm=
AML3 MULGeY5kfGmxbjDBd5NigQ>? MnPVNVDPxE1? MlvpNk81KGh? NEnyT3FqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MYSyOFY2QTd2OR?=
MOML13 MoGzSpVv[3Srb36gRZN{[Xl? M{XE[lEx|ryP MljFNk81KGh? NEfNVGJqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M4LL[FI1PjV7N{S5
BeWo MnSySpVv[3Srb36gRZN{[Xl? NGqxeno{OCEEtV2= NHnwRZgzPCCq MVXpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= MX2yOFQ6QDF3NB?=
BeWo M2PNZ2Fxd3C2b4Ppd{BCe3OjeR?= NFTzd2M{OCEEtV2= NH\XWHIzPCCq MmPObY5kemWjc3XzJIFxd3C2b4Ppdy=> MX[yOFQ6QDF3NB?=
OCI NFXHbnBHfW6ldHnvckBCe3OjeR?= NHzmO2kyOCEQvF2= MXmyOEBp Mn3ieZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MViyOFQ4OzV4Mh?=
MOLM NHXXdoxHfW6ldHnvckBCe3OjeR?= NUezVJdFOTBizszN M4DETlI1KGh? M1P3XZVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NUnidmtEOjR2N{O1OlI>
U2OS  MXLGeY5kfGmxbjDBd5NigQ>? M2HnbFIxKM7:TR?= MnvtNlQhcA>? NVLEO45DcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NGLtXWQzPDN4NkCwOy=>
RKO NHO1[GRHfW6ldHnvckBCe3OjeR?= MlTaNlAh|ryP MkL2NlQhcA>? M{TBWYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MmD4NlQ{PjZyMEe=
U2OS  MWTGeY5kfGmxbjDBd5NigQ>? NX\nZZRYOjBizszN MmPRNlQhcA>? NE[yNmdqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NILBS|QzPDN4NkCwOy=>
RKO MlnXSpVv[3Srb36gRZN{[Xl? NXTwfnlZOjBizszN NWjPSYt7OjRiaB?= Mon0bY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MmrtNlQ{PjZyMEe=
SMMC-7721  M4TRfGNmdGxiVnnhZoltcXS7IFHzd4F6 MkTyNU4zPS1{MDFOwG0> MoPBNlQwPDhxN{KgbC=> NWTNZ4ZCTE2VTx?= NFTHXnpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MV:yOFI5PjNzMh?=
HuH-7 NIXJWoFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NU\oPWlLOS5{NT2yNEDPxE1? MVWyOE81QC95MjDo NXLMZXBlTE2VTx?= NEP2dXJqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NFXVOJczPDJ6NkOxNi=>
SMMC-7721  NIe1RodCeG:ydH;zbZMhSXO|YYm= NXv2Tm9qOjBizszN NFPmZWY1QCCq MXXEUXNQ NHzTSpJqdmS3Y3XzJIFxd3C2b4Ppdy=> M{P6WlI1Ojh4M{Gy
HuH-7 MYnBdI9xfG:|aYOgRZN{[Xl? MmPlNlAh|ryP MmnkOFghcA>? NFTPfnhFVVOR M2jEUolv\HWlZYOgZZBweHSxc3nz NGHX[GMzPDJ6NkOxNi=>
SMMC-7721  NX30RlQ5TnWwY4Tpc44hSXO|YYm= MVqxNEDPxE1? NETVVZI{PiCq MmO4SG1UVw>? NVTxPXBZ\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? NV;4[YdOOjR{OE[zNVI>
HuH-7 Moj2SpVv[3Srb36gRZN{[Xl? NVvPcYV{OTBizszN NEjBVGI{PiCq M3\jWWROW09? M3roT4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MWiyOFI5PjNzMh?=
AT2 MmrtSpVv[3Srb36gRZN{[Xl? NVrncVZyPS9zMDFOwG0> M1y3Soxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li MXuyOFI1ODJyMx?=
REH MkDKSpVv[3Srb36gRZN{[Xl? NVfwbnJSPS9zMDFOwG0> NGTBVWdt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NH;SVnQzPDJ2MEKwNy=>
UoCB6 M3q5[mZ2dmO2aX;uJGF{e2G7 MYi1M|ExKM7:TR?= MoTkcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NVzyUIp5OjR{NECyNFM>
AT2 NHPoW|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mlq1NE0zPSEQvF2= M2GxfYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NVP4Wmo3OjR{NECyNFM>
REH MlL5R4VtdCCYaXHibYxqfHliQYPzZZk> NWfyZnYyOC1{NTFOwG0> MXfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NUDIOIs1OjR{NECyNFM>
UoCB6 NEfJTVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYGwMVI2KM7:TR?= NVP2e2Y4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGjtUHkzPDJ2MEKwNy=>
A2780 M{fyUWZ2dmO2aX;uJGF{e2G7 MmfBOU8yOC9{MDFOwG0> MknWNlQhcA>? MoHkeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NXLCVGVxOjRzM{[xOFc>
H460 NFnIN4pHfW6ldHnvckBCe3OjeR?= NHztV|E2NzFyL{KwJO69VQ>? NFPubY0zPCCq NFn2fmJ2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NISxUogzPDF|NkG0Oy=>
Lovo  NWT5e2tzTnWwY4Tpc44hSXO|YYm= M2C5VFUwOTBxMkCg{txO M3HHSFI1KGh? M3vpWJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NGT2[oUzPDF|NkG0Oy=>
A2780 M3TMcmFxd3C2b4Ppd{BCe3OjeR?= NF;UTnM2NzFyL{KwJO69VQ>? MXiyOEBp NIXuPIVmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NG\Z[pEzPDF|NkG0Oy=>
H460 M3zFSmFxd3C2b4Ppd{BCe3OjeR?= NHP2Tmo2NzFyL{KwJO69VQ>? M{PGTVI1KGh? M{L4O4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NX\hO3MyOjRzM{[xOFc>
Lovo  NID6ZWtCeG:ydH;zbZMhSXO|YYm= NXvxS41lPS9zMD:yNEDPxE1? M{C4RlI1KGh? Mmq2[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NGDEd|MzPDF|NkG0Oy=>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay
+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research
+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method: Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID